Ziegler Capital Management’s Blueprint Medicines BPMC Stock Holding History

Ziegler Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,904	Closed	-$377K	–	389
2022 Q1	$377K	Hold	5,904	–	–	0.02%	343
2021 Q4	$632K	Sell	5,904 -2,566	-30%	-$268K	0.02%	357
2021 Q3	$871K	Sell	8,470 -506	-6%	-$47.1K	0.03%	345
2021 Q2	$790K	Buy	+8,976	New	+$822K	0.03%	354

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ziegler Capital Management's BPMC Position: Q2 2022 in Review

Ziegler Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2022, closing a stake of 5,904 shares — an estimated $377K sold.

Ziegler Capital Management first reported a position in BPMC in Q2 2021 and held it in 4 quarters. The position peaked at $871K in Q3 2021. 237 funds tracked by Wall St. Rank hold BPMC as of Q2 2022.

Ziegler Capital Management reported no remaining Blueprint Medicines position as of Q2 2022 after selling out during the quarter.
Ziegler Capital Management sold 5,904 Blueprint Medicines shares in Q2 2022, an estimated $377K.
Ziegler Capital Management first reported a position in Blueprint Medicines in Q2 2021 and held it in 4 quarters.
Ziegler Capital Management's Blueprint Medicines position peaked at $871K in Q3 2021.
237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2022.

Based on Ziegler Capital Management's 13F filing for Q2 2022, filed 21 Jul 2022.